The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Open accessAbstract
The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation. Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are associated with toxicity due to concurrent inhibition of wild-type EGFR. All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR. Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M. These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro. They are also effective in murine models of lung cancer driven by EGFR T790M. Co-crystallization studies reveal a structural basis for the increased potency and mutant selectivity of these agents. These mutant-selective irreversible EGFR kinase inhibitors may be clinically more effective and better tolerated than quinazoline-based inhibitors. Our findings demonstrate that functional pharmacological screens against clinically important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2009, Pasi et al. identified a series of covalent pyrimidine EGFR inhibitors, including WZ 3146, WZ 4002, and WZ 8040, through screening a library of irreversible kinase inhibitors specific to EGFRT790M.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [203]
In the citing paper
“These agents are designed to specifically inhibit mutant EGFR (ie, 19del-EGFR, L858R-EGFR and/or T790M+EGFR), sparing the WT receptor.14–18”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [14]
In the citing paper
“The presence of the T790M mutation was observed in approximately 50% of the cases in which biopsy was obtained at the time of relapse following gefitinib or erlotinib treatment in patients with the exon 19 deletion or the L858R EGFR mutation.”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [14]
In the citing paper
“AZD9291 has a distinct chemical structure from the other third-generation TKIs, WZ4002 (34) and CO-1686 (35).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [34]
In the citing paper
“C797 is located opposite T790 in the ATP binding pocket and forms a covalent bond with all third-generation TKIs and is necessary for the inhibitor to suppress EGFR (21).”
In the citing paper
“This approach has previously led to identification of clinically relevant drug resistance mutations to EGFR TKIs (30, 31).”
From Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors (2017) · cites this paper as [30]
In the citing paper
“Thus, the T790M structural alteration in essence “enabled” discovery of inhibitors that selectively inhibit T790M–bearing mutants, when in association with L858R or exon 19 deletions, relative to WT EGFR 58,59.”
From Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer (2013) · cites this paper as [58]
In the citing paper
“Examination of the crystal structure of WZ4002 in complex with EGFR T790M (14) reveals that both L718 and L844 are in direct contact with the inhibitor; L718 primarily with the aniline ring and L844 with the pyrimidine ring (Figure 2A).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“Cysteine 797 is the site of covalent binding for all three of these agents (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“They are not only more potent on EGFR T790M, but also selectively inhibit mutant over WT EGFR and hence should lead to increased clinical efficacy and less toxicity compared with afatinib (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“C797 is the site of covalent binding of WZ4002 and previously demonstrated to lead to drug resistance if mutated to serine (14).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“CO-1686 is structurally more closely related to WZ4002 than to AZD9291 and in all of the models tested CO-1686 is very similar in vitro to WZ4002 (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“However, ENU mutagenesis studies have been predictive of clinical drug resistance mutations in several prior studies (14, 24).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“In prior studies, introduction of C797S into the background of EGFR L858R/T790M or EGFR Del 19/T790M resulted in significant loss of cellular potency for WZ4002 (14).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“Analogously, a non-covalent analogue of WZ4002, WZ4003, was ineffective in in vitro models of EGFR T790M (14).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“These include the development of mutant selective EGFR kinase inhibitors, including WZ4002, CO-1686 and AZD9291, which to date have demonstrated encouraging efficacy in both preclinical models and in EGFR mutant NSCLC patients with EGFR T790M mediated drug resistance (14–18).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“WZ4002 is a covalent pyrimidine EGFR inhibitor specifically designed against EGFR T790M that is 30–100 fold more potent against EGFR T790M, and up to 100 fold less potent against wild type EGFR than quinazoline based EGFR inhibitors in vitro and is effective in murine models of lung cancer driven by EGFR T790M [84].”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [84]
In the citing paper
“Both 2G and 3G EGFR‐TKI are irreversible small‐molecule inhibitors that covalently bind to EGFR kinase by targeting the cysteine‐797 residue, located in the ATP binding pocket, and 3G EGFR‐TKI are considered to be more specific for EGFR sensitizing mutations than 2G EGFR‐TKI.12, 13, 14”
In the citing paper
“A third generation of EGFR inhibitors followed afatinib; these covalent inhibitors selectively target the T790M mutant over wild-type EGFR, and include WZ4002 (Dana–Farber Cancer Institute)43, osimertinib44,45 and rociletinib (Clovis Oncology; CO-1686)46 (Fig. 2c).”
From Advances in covalent drug discovery (2022) · cites this paper as [43]
In the citing paper
“Standard of care is rapidly changing with the development of third-generation, mutant-selective EGFR-TKIs that have activity against cells that harbor TKI-sensitive EGFR mutations. Unlike conventional EGFR-TKIs, this activity is maintained in the presence of T790M resistance mutation.8,9”
From Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer (2016) · cites this paper as [9]
In the citing paper
“Next-generation EGFR TKIs have since been developed specifically to target the T790M mutation, 17,18 and they have demonstrated high and durable responses in patients with advanced EGFRmutant NSCLC who have been previously treated and in whom firstor second-generation EGFR TKIs have failed.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
Self-citationBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Self-citationDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
Self-citationEngelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,000
Wang, L., Zhao, J., Yao, Y., Wang, C., Zhang, J., Shu, X. H., Sun, X., Li, Y., Liu, K., Yuan, H., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.024 · Cited by 39
Hirano, T., Yasuda, H., Hamamoto, J., Nukaga, S., Masuzawa, K., Kawada, I., Naoki, K., Niimi, T., Mimasu, S., Sakagami, H., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1033 · Cited by 39
Hammoud, M. K., Yosef, H. K., Lechtonen, T., Aljakouch, K., Schuler, M., Alsaidi, W., Daho, I., Maghnouj, A., Hahn, S. A., El‐Mashtoly, S. F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33682-7 · Cited by 42
Ai, M., Wang, C., Tang, Z., Liu, K., Sun, X., Ma, T., Li, Y., Ma, X., Li, L., & Chen, L. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103408 · Cited by 39
Self-citationApplications of Reactive Cysteine Profiling
Backus, K. M. (2018) · Current topics in microbiology and immunology · doi:10.1007/82_2018_120 · Cited by 39
Dual-molecular barcode sequencing detects rare variants in tumor and cell free DNA in plasma
Hirotsu, Y., Otake, S., Ohyama, H., Amemiya, K., Higuchi, R., Oyama, T., Mochizuki, H., Goto, T., & Omata, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-60361-3 · Cited by 38
Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines
Sato, M., Fuchida, H., Shindo, N., Kuwata, K., Tokunaga, K., Xiao-Lin, G., Inamori, R., Hosokawa, K., Watari, K., Shibata, T., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00574 · Cited by 38
Bahcall, M., Paweletz, C. P., Kuang, Y., Taus, L. J., Sim, T., Kim, N. D., Dholakia, K. H., Lau, C. J., Gokhale, P. C., Chopade, P. R., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0344 · Cited by 38
James, K. A., & Verkhivker, G. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113488 · Cited by 40
Heller, P., WEINSTEIN, H. G., WEST, M., & Zimmerman, H. J. (1960) · PubMed · Cited by 38
Izar, B., Rotow, J. K., Gainor, J. F., Clark, J. W., & Chabner, B. A. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007807 · Cited by 38
Todsaporn, D., Mahalapbutr, P., Poo-arporn, R. P., Choowongkomon, K., & Rungrotmongkol, T. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105787 · Cited by 38
Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer
Haghgoo, S. M., Allameh, A., Mortaz, E., Garssen, J., Folkerts, G., Barnes, P. J., & Adcock, I. M. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.029 · Cited by 39
Xu, T., Zhang, L., Xu, S., Yang, C., Luo, J., Ding, F., Lu, X., Liu, Y., Tu, Z., Li, S., et al. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201302313 · Cited by 37
Hao, Y., Lyu, J., Qu, R., Tong, Y., Sun, D., Fěng, F., Tong, L., Yang, T., Zhao, Z., Zhu, L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00346 · Cited by 37
A structural perspective on targeting the RTK /Ras/ MAP kinase pathway in cancer
Heppner, D. E., & Eck, M. J. (2021) · Protein Science · doi:10.1002/pro.4125 · Cited by 39
Self-citationAmrhein, J. A., Beyett, T. S., Feng, W. W., Krämer, A., Weckesser, J., Schaeffner, I. K., Rana, J. K., Janne, P. A., Eck, M. J., Knapp, S., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01041 · Cited by 36
Self-citationNurwidya, F., Takahashi, F., Murakami, A., Kobayashi, I., Kato, M., Shukuya, T., Tajima, K., Shimada, N., & Takahashi, K. (2013) · Respiratory Investigation · doi:10.1016/j.resinv.2013.07.007 · Cited by 37
Pharmacogenetics of EGFR in Lung Cancer: Perspectives and Clinical Applications
Mayo, C., Bertrán-Alamillo, J., Molina‐Vila, M. Á., Giménez-Capitán, A. A., Costa, C., & Rosell, R. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.54 · Cited by 36
Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment
Li, J., & Kwok, H. F. (2020) · Cancers · doi:10.3390/cancers12061587 · Cited by 37
Xiao, Z., Zhou, Z., Chu, C., Zhang, Q., Zhou, L., Yang, Z., Li, X., Yu, L., Zheng, P., Xu, S., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112511 · Cited by 36
Li, J., An, B., Song, X., Zhang, Q., Chen, C., Wei, S., Fan, R., Li, X., & Zou, Y. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113019 · Cited by 36
Hoyt, K. W., Urul, D. A., Ogboo, B. C., Wittlinger, F., Laufer, S., Schaefer, E., May, E. W., & Heppner, D. E. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01502 · Cited by 35
Wang, H., Lai, Y., Li, D., Karges, J., Zhang, P., & Huang, H. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01889 · Cited by 35
Self-citationWittlinger, F., Ogboo, B. C., Shevchenko, E., Damghani, T., Pham, C. D., Schaeffner, I. K., Oligny, B. T., Chitnis, S. P., Beyett, T. S., Rasch, A., et al. (2024) · Communications Chemistry · doi:10.1038/s42004-024-01108-3 · Cited by 35
Self-citationIdentification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2
Tanizaki, J., Ercan, D., Capelletti, M., Dodge, M. E., Xu, C., Bahcall, M., Tricker, E. M., Butaney, M., Calles, A., Sholl, L. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3771 · Cited by 35
Self-citationLiang, Z., Cheng, Y., Chen, Y., Hu, Y., Liu, W.-P., Lü, Y., Wang, J., Wang, Y., Wu, G., Ying, J., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.008 · Cited by 36
Development of Specific, Irreversible Inhibitors for a Receptor Tyrosine Kinase EphB3
Kung, A., Chen, Y., Schimpl, M., Ni, F., Zhu, J., Turner, M., Molina, H., Overman, R., & Zhang, C. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b05483 · Cited by 34
Das, D., Wang, J., & Hong, J. (2021) · ChemMedChem · doi:10.1002/cmdc.202100166 · Cited by 35
Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFRT790M/C797S Mutants
Li, S., Zhang, T., Zhu, S., Lei, C., Lai, M., Peng, L., Tong, L., Pang, Z., Lu, X., Ding, J., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00555 · Cited by 34
Self-citationWang, R., Zhao, Y., Huang, Z., Zhou, Y., Wang, W., Yang, X., Zhen, Y., Ju, B., Guo, S., & Zhang, S. (2022) · ACS Nano · doi:10.1021/acsnano.1c09391 · Cited by 34
Sentana‐Lledo, D., Academia, E. C., Viray, H., Rangachari, D., Kobayashi, S. S., VanderLaan, P. A., & Costa, D. B. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-98 · Cited by 34
Xu, T., Peng, T., Ren, X., Zhang, L., Yu, L., Luo, J., Zhang, Z., Tu, Z., Tong, L., Huang, Z., et al. (2015) · MedChemComm · doi:10.1039/c5md00208g · Cited by 34
Sun, D., Yu, Y., Lyu, J., Zhou, W., Song, W., Zhao, Z., Chen, Z., Xu, Y. F., & Li, H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00374 · Cited by 34
Self-citationFBXW 7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
Xiao, Y., Yin, C., Wang, Y., Lv, H., Wang, W., Huang, Y., Pérez‐Losada, J., Snijders, A. M., Mao, J., & Zhang, P. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12200 · Cited by 34
Xu, S., Xu, T., Zhang, L., Zhang, Z., Luo, J., Liu, Y., Lu, X., Tu, Z., Ren, X., & Ding, K. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4012388 · Cited by 33
Toenjes, S. T., Garcia, V., Maddox, S. M., Dawson, G. A., Ortiz, M. A., Piedrafita, F. J., & Gustafson, J. L. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00407 · Cited by 34
Sun, X., Xu, S., Yang, Z., Zheng, P., & Zhu, W. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1860210 · Cited by 34
Yang, T., Zhang, W., Cao, S., Sun, S., Cai, X., Xu, L., Li, P., Zheng, Z., & Li, S. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113984 · Cited by 33
Pawara, R. H., Ahmad, I., Nayak, D., Belamkar, S., Surana, S. J., Kundu, C. N., Patil, C., & Patel, H. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.132313 · Cited by 33
Small-Molecule Inhibitors of the c-Fes Protein-Tyrosine Kinase
Hellwig, S., Miduturu, C., Kanda, S., Zhang, J., Filippakopoulos, P., Salah, E., Deng, X., Choi, H. G., Zhou, W., Hur, W., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.020 · Cited by 33
Self-citationYang, M., Pickard, A. J., Qiao, X., Gueble, M. J., Day, C. S., Kucera, G. L., & Bierbach, U. (2015) · Inorganic Chemistry · doi:10.1021/ic502998a · Cited by 33
Yu, H., Li, Y., Yang, G., Song, Z., Wang, C., Huang, S., Jin, Y., Han, X., Zhen, Y., Liu, K., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.045 · Cited by 33
Structure-guided development of covalent TAK1 inhibitors
Tan, L., Gurbani, D., Weisberg, E., Hunter, J. C., Li, L., Jones, D. S., Ficarro, S. B., Mowafy, S., Tam, C. P., Rao, S., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.11.035 · Cited by 33
Self-citationDamare, R., Engle, K., & Kumar, G. (2024) · Phytotherapy Research · doi:10.1002/ptr.8166 · Cited by 32
Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging
Bernard‐Gauthier, V., Bailey, J. J., Berke, S., & Schirrmacher, R. (2015) · Molecules · doi:10.3390/molecules201219816 · Cited by 32
Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer
Angus, S. P., Zawistowski, J. S., & Johnson, G. L. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052954 · Cited by 32
Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
Baldacci, S., Mazières, J., Tomasini, P., Girard, N., Guisier, F., Audigier-Valette, C., Monnet, I., Wislez, M., Pérol, M., Dô, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21707 · Cited by 32
Self-citationPatel, H., Ansari, A., Pawara, R. H., Ansari, I., Jadhav, H., & Surana, S. J. (2018) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2018.1557207 · Cited by 32
Patel, H., Ahmad, I., Jadhav, H., Pawara, R. H., Lokwani, D. K., & Surana, S. J. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323666201204125524 · Cited by 32
Unnisa, A., Chettupalli, A. K., Hussain, T., & Kamal, M. A. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220408090541 · Cited by 32
Li, B., Yang, T., Liu, J., Yu, X., Li, X., Qin, F., Zheng, J., Liang, J., Zeng, Y., Zhou, Z., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.03.002 · Cited by 33
Self-citationAn In Vivo C. elegans Model System for Screening EGFR-Inhibiting Anti-Cancer Drugs
Bae, Y., Sung, J. Y., Kim, Y.-N., Kim, S., Hong, K. M., Kim, H. T., Choi, M. S., Kwon, J. Y., & Shim, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042441 · Cited by 32
Jeong, C. (2015) · Journal of Cancer Prevention · doi:10.15430/jcp.2015.20.1.57 · Cited by 33
Xiao, Q., Qu, R., Gao, D., Qi, Y., Tong, L., Zhang, W., Ding, J., Xie, H., & Li, Y. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.04.032 · Cited by 32
Engel, J., Smith, S. P., Lategahn, J., Tumbrink, H. L., Goebel, L., Becker, C., Hennes, E., Keul, M., Unger, A., Müller, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00515 · Cited by 32
Discovery of Novel Fourth-Generation EGFR Inhibitors to Overcome C797S-Mediated Resistance
Zhu, Y., Ye, X., Shen, H., Li, J., Cai, Z., Min, W., Hou, Y., Dong, H., Wu, Y., Wang, L., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01165 · Cited by 32
Ahmed, M., Sadek, M. M., Abouzid, K. A. M., & Wang, F. (2013) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2013.06.004 · Cited by 31
Zannetti, A., Iommelli, F., Speranza, A., Salvatore, M., & Vecchio, S. D. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.096503 · Cited by 31
Liu, L., Qu, J., Heng, J., Zhou, C., Xiong, Y., Yang, H., Jiang, W., Zeng, L., Zhu, S., Zhang, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.722039 · Cited by 31
Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor
Lim, S. M., Westover, K. D., Ficarro, S. B., Harrison, R. A., Choi, H. G., Pacold, M. E., Carrasco, M. A., Hunter, J., Kim, N. D., Xie, T., et al. (2013) · Angewandte Chemie · doi:10.1002/ange.201307387 · Cited by 30
Self-citationNF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor
Galvani, E., Sun, J., León, L. G., Sciarrillo, R., Narayan, R. S., Sjin, R. T. T., Lee, K., Ohashi, K., Heideman, D. A. M., Alfieri, R. R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3956 · Cited by 32
Discovery of novel selective inhibitors for EGFR-T790M/L858R
Bai, F., Liu, H., Tong, L., Zhou, W., Liu, L., Zhao, Z., Liu, X., Jiang, H., Wang, X., Xie, H., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.12.067 · Cited by 32
Self-citationSong, Z., Jin, Y., Yang, G., Wang, C., Zhang, J., Tang, Z., Peng, J., Liu, K., Li, Y., & Ma, X. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.09.001 · Cited by 31
Jang, J., Son, J., Park, E., Kosaka, T., Saxon, J. A., Clercq, D. J. H. D., Choi, H. G., Tanizaki, J., Eck, M. J., Janne, P. A., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201805187 · Cited by 32
Self-citationA detailed multi-omics analysis of GNB2 gene in human cancers
Zhang, L., Sahar, A. M., Li, C., Chaudhary, A. K., Yousaf, I., Saeedah, M. A., Mubarak, A., Haris, M., Nawaz, M. S., Reem, M. A., et al. (2022) · Brazilian Journal of Biology · doi:10.1590/1519-6984.260169 · Cited by 30
Chauhan, M., Rana, A., Alex, J. M., Negi, A., Singh, S., & Kumar, R. (2014) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2014.11.004 · Cited by 30
Inhibiting Epidermal Growth Factor Receptor at a Distance
Sinclair, J. K.-L., Denton, E. V., & Schepartz, A. (2014) · Journal of the American Chemical Society · doi:10.1021/ja504076t · Cited by 30
Stasi, I., & Cappuzzo, F. (2014) · Translational Respiratory Medicine · doi:10.1186/2213-0802-2-2 · Cited by 30
Yang, G., Wang, C., Song, S., Huang, J., Liu, Z., Li, Y., Meng, Q., Zhang, J., Yao, J., Liu, K., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.080 · Cited by 31
Re, M. D., Petrini, I., Mazzoni, F., Valleggi, S., Gianfilippo, G., Pozzessere, D., Chella, A., Crucitta, S., Rofi, E., Restante, G., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.10.003 · Cited by 30
Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK and BRAF
Giroux, S. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.11.037 · Cited by 30
Kawabata, S., Mercado-Matos, J., Hollander, M. C., Donahue, D., Wilson, W., Regales, L., Butaney, M., Pao, W. J., Wong, K., Janne, P. A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.039 · Cited by 30
Self-citationFadaly, W. A. A., Nemr, M. T. M., El-Hameed, A. M. A., Mohamed, F. E. A., & Zidan, T. H. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108563 · Cited by 32
Strategies for improving outcomes in NSCLC: A look to the future
Stahel, R. A., Peters, S., Baas, P., Brambilla, E. M., Cappuzzo, F., Ruysscher, D. D., Eberhardt, W., Felip, E., Fennell, D. A., Marchetti, A., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.025 · Cited by 29
Hao, Y., Wang, X., Zhang, T., Sun, D., Tong, Y., Xu, Y., Chen, H., Tong, L., Zhu, L., Zhao, Z., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00403 · Cited by 29
Yang, G., Jin, Y., Wang, C., Zhang, J., Tang, Z., Peng, J., Liu, K., Li, Y., Zhou, Y., & Ma, X. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00235 · Cited by 29
Zhao, D. Y., Huang, S., Qu, M., Wang, C., Liu, Z., Li, Z., Peng, J., Liu, K., Li, Y., Ma, X., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.11.047 · Cited by 29
Recent advances in the management of non-small cell lung cancer
Shojaee, S., & Nana-Sinkam, P. S. (2017) · F1000Research · doi:10.12688/f1000research.11471.1 · Cited by 29
Song, J., Jang, S., Lee, J. W., Jung, D., Lee, S., & Min, K. H. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.020 · Cited by 29
So, K. S., Kim, C. H., Rho, J. K., Kim, S. Y., Choi, Y. J., Song, J. S., Kim, W. S., Choi, C., Chun, Y. J., & Lee, J. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114000 · Cited by 29
Galvani, E., Alfieri, R. R., Giovannetti, E., Cavazzoni, A., Monica, S. L., Galetti, M., Fumarola, C., Bonelli, M. A., Mor, M., Tiseo, M., et al. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804547222 · Cited by 30
Zhou, P., Chen, G., Gao, M., & Wu, J. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.10.018 · Cited by 29
Assadollahi, V., Rashidieh, B., Alasvand, M., Abdolahi, A., & López, J. A. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28575 · Cited by 29
Marrocco, I., & Yarden, Y. (2023) · Cancers · doi:10.3390/cancers15205009 · Cited by 28
Oh, D. K., Ji, W., Kim, W. S., Choi, C., Yoon, S., Rho, J. K., & Lee, J. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210225 · Cited by 28
Tabti, K., Abdessadak, O., Sbai, A., Maghat, H., Bouachrıne, M., & Lakhlifi, T. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.135404 · Cited by 28
Evolution of targeted therapies in cancer: opportunities and challenges in the clinic
Santhosh, S., Kumar, P. R. G., Ramprasad, V. L., & Chaudhuri, A. (2015) · Future Oncology · doi:10.2217/fon.14.198 · Cited by 29
Phuangsawai, O., Beswick, P., Ratanabunyong, S., Tabtimmai, L., Suphakun, P., Obounchoey, P., Srisook, P., Horata, N., Chuckowree, I., Hannongbua, S., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.055 · Cited by 28
Fukuda, T., Umeki, T., Tokushima, K., Gao, X., Yoshida, Y., Ishibashi, F., Oku, Y., Nishiya, N., Uehara, Y., & Iwao, M. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.030 · Cited by 28
Fawwaz, M., Mishiro, K., Nishii, R., Sawazaki, I., Shiba, K., Kinuya, S., & Ogawa, K. (2020) · Molecules · doi:10.3390/molecules25122914 · Cited by 28
Gawli, C., Patil, C. R., & Patel, H. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118146 · Cited by 27
Brueckl, W. M., Tufman, A., & Huber, R. M. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1266265 · Cited by 27
Expression Levels of Therapeutic Targets as Indicators of Sensitivity to Targeted Therapeutics
Roy, R., Winteringham, L. N., Lassmann, T., & Forrest, A. R. R. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0273 · Cited by 28
Scalvini, L., Castelli, R., Monica, S. L., Tiseo, M., & Alfieri, R. R. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114643 · Cited by 28
Todsaporn, D., Zubenko, A. A., Kartsev, V. G., Aiebchun, T., Mahalapbutr, P., Petrou, A., Geronikaki, A. A., Диваева, Л. Н., Chekrisheva, V., Yıldız, İ., et al. (2023) · Molecules · doi:10.3390/molecules28073014 · Cited by 28
Kim, J., Jang, S. J., Choi, C., & Ro, J. Y. (2016) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000121 · Cited by 27
Structure–Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent
Liang, Y., de Wispelaere, M., Carocci, M., Liu, Q., Wang, J., Yang, P. L., & Gray, N. S. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00008 · Cited by 28
Self-citationDesign, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors
Romu, A., Lei, Z., Zhou, B., Chen, Z., & Korlipara, V. L. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.09.048 · Cited by 27
Metadata
- Authors
- Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., Engen, J. R., Wong, K.-K., Eck, M. J., Gray, N. S., & Jänne, P. A.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Northeastern University (US)
- Corresponding author
- Gray, Nathanael S.
- ORCID
- Venue
- Nature
- Published
- 2009-12
- Volume
- 462
- Issue
- 7276
- Pages
- 1070-1074
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2879581
- OpenAlex
- W2133963438
- Cited by
- 1,013
- References
- 30
- Citations by year
- 2026: 32 · 2025: 43 · 2024: 39 · 2023: 60 · 2022: 46 · 2021: 55 · 2020: 62 · 2019: 55 · 2018: 66 · 2017: 84 · 2016: 82 · 2015: 75 · 2014: 71 · 2013: 82 · 2012: 54
- FWCI
- 45.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (R01AG2400401)
- National Cancer Institute (R01CA116020, R01CA122794, R01CA130876, R01CA11446, P50CA090578, R01CA135257, R01CA080942)
- National Institute of General Medical Sciences (R01GM070590)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- EGFR kinase inhibitors, mutant-selective inhibitors, irreversible kinase inhibitors, non-small cell lung cancer, drug resistance, co-crystallization, gatekeeper mutation
- MeSH terms
- Animals, Antineoplastic Agents, Drug Evaluation, Preclinical, Lung, Models, Chemical, Models, Molecular, Mutation, Phosphorylation, Drug Resistance, Neoplasm, NIH 3T3 Cells, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Mice, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
